Indivior Inc. v. Actavis Laboratories UT, Inc.
1:18-cv-00499
๐ก 5G SEP โข ETSI DeclaredOverview
Parties
Defendant
Actavis Laboratories UT, Inc. Operating Company
Represented By
4 Attorneys ListedPhillips, Goldman, McLaughlin & Hall, P.A.
Phillips, Goldman, McLaughlin & Hall, P.A., 1200 North Broom Street
Phillips, McLaughlin & Hall, P.A.
Phillips, McLaughlin & Hall, P.A., 1200 N. Broom St
Plaintiff
Indivior Inc. Operating Company
Represented By
7 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Counter Defendant
Indivior UK Limited NPE (University / Research)
Represented By
7 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360ยฐ Radar 8 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| ๐บ๐ธ United States | US 9,687,454 B2 Asserted | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 2017020943 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 11,135,216 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 8,475,832 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 2013028148 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 2014000521 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 2014037849 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 2015024600 | US Continuation / Sibling | View Official Patent → |
Dr. Reddy's Laboratories S.A. et al. v. Indivior UK Limited et al.
Dr. Reddyโs Laboratories S.A. et al. v. Indivior UK Limited et al.
Dr. Reddyโs Laboratories, Inc. et al. v. Indivior UK Limited et al.
Teva Pharmaceuticals USA, Inc. v. Indivior UK Limited et al.
BioDelivery Sciences International, Inc. v. RB Pharmaceuticals Limited
BioDelivery Sciences International, Inc. v. RB Pharmaceuticals Limited
Standard Essential Patent (SEP) & FRAND Intelligence
5G SEP โข ETSI Declared High-Probability SEP ActionEssential standard specifications, SSO declaration status, and FRAND antitrust defense evaluation
Injunction Restrictions & FRAND Defense Leverage (CJEU Huawei v. ZTE Framework)
Permanent Injunction RestrictedAsserted by recognized SEP declarant. Under the CJEU Huawei v. ZTE test, injunctions are barred if the defendant qualifies as a willing licensee.
Patents Involved
There is a single patent involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US9687454
Sublingual and buccal film compositions
|
Filed: 2016-01-06
Issued: 2017-06-27
|
Active (9.1 yrs remaining)
Expires: 2036-01-06
|
Patent Enforceability & Injunction Risk Assessment
Active Threat โ Patent is within enforceable statutory term. Patentee retains legal standing to seek permanent injunctive relief and exclusion orders.
Standard Statutory Term โ No obviousness-type double patenting truncation noted.
Under 35 U.S.C. ยง 286, damages cannot accrue for infringement prior to 6 years before filing. 4th & 8th Year Maintenance Fees Paid (12th Year Window Upcoming).
Procedural Motions & Interlocutory Orders
Total Motions
4
Dispositive
2
Granted
4
Denied
0
Pending / Review
0
Motions by Category
Key Dispositive Motions & Rulings